Keel Point LLC raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,286 shares of the biopharmaceutical company’s stock after buying an additional 18 shares during the period. Keel Point LLC’s holdings in Bristol-Myers Squibb were worth $342,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Dodge & Cox acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $1,316,815,000. Norges Bank acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $770,318,000. Ameriprise Financial Inc. raised its position in Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the last quarter. Swiss National Bank raised its position in Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new position in Bristol-Myers Squibb during the first quarter worth $38,890,000. Hedge funds and other institutional investors own 69.79% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) traded down 0.37% during midday trading on Thursday, hitting $57.19. 1,373,899 shares of the company’s stock were exchanged. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $61.30. The stock’s 50 day moving average is $55.81 and its 200-day moving average is $54.58. The stock has a market cap of $93.79 billion, a PE ratio of 20.89 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 earnings per share. Analysts predict that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.72%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

ILLEGAL ACTIVITY NOTICE: “Keel Point LLC Acquires 18 Shares of Bristol-Myers Squibb Company (BMY)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/keel-point-llc-acquires-18-shares-of-bristol-myers-squibb-company-bmy.html.

BMY has been the topic of a number of recent research reports. BMO Capital Markets lowered shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Wednesday, May 3rd. Robert W. Baird started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 25th. They set an “outperform” rating on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a report on Monday, June 5th. Finally, BidaskClub lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $62.67.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.